These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585 [TBL] [Abstract][Full Text] [Related]
8. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen. Tekewe A; Fan Y; Tan E; Middelberg AP; Lua LH Biotechnol Bioeng; 2017 Feb; 114(2):397-406. PubMed ID: 27497268 [TBL] [Abstract][Full Text] [Related]
9. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071 [TBL] [Abstract][Full Text] [Related]
10. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. Walker A; Skamel C; Vorreiter J; Nassal M J Biol Chem; 2008 Nov; 283(48):33508-15. PubMed ID: 18826949 [TBL] [Abstract][Full Text] [Related]
11. Capsid-Incorporation Strategy To Display Antigens for an Alternative Adenoviral Vector Vaccine Approach. van Winkel CAJ; Moreno A; Curiel DT Mol Pharm; 2018 Dec; 15(12):5446-5453. PubMed ID: 30359030 [TBL] [Abstract][Full Text] [Related]
12. The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration. Janitzek CM; Carlsen PHR; Thrane S; Khanna VM; Jakob V; Barnier-Quer C; Collin N; Theander TG; Salanti A; Nielsen MA; Sander AF Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33562114 [TBL] [Abstract][Full Text] [Related]
13. Alphavirus capsid proteins self-assemble into core-like particles in insect cells: A promising platform for nanoparticle vaccine development. Hikke MC; Geertsema C; Wu V; Metz SW; van Lent JW; Vlak JM; Pijlman GP Biotechnol J; 2016 Feb; 11(2):266-73. PubMed ID: 26287127 [TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems. Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871 [TBL] [Abstract][Full Text] [Related]
15. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. Lei X; Cai X; Yang Y Expert Rev Vaccines; 2020 Mar; 19(3):235-246. PubMed ID: 32133886 [No Abstract] [Full Text] [Related]
16. Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro. Zheng M; Jiang J; Zhang X; Wang N; Wang K; Li Q; Li T; Lin Q; Wang Y; Yu H; Gu Y; Zhang J; Li S; Xia N Vaccine; 2018 Apr; 36(16):2104-2111. PubMed ID: 29544686 [TBL] [Abstract][Full Text] [Related]
17. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). Zhang X; Wei M; Pan H; Lin Z; Wang K; Weng Z; Zhu Y; Xin L; Zhang J; Li S; Xia N; Zhao Q Vaccine; 2014 Jul; 32(32):4039-50. PubMed ID: 24892250 [TBL] [Abstract][Full Text] [Related]
18. Efficient application of a baculovirus-silkworm larvae expression system for obtaining porcine circovirus type 2 virus-like particles for a vaccine. He Q; Cao Z; Wang P; Lu Q; Zheng H; Sun J Arch Virol; 2020 Oct; 165(10):2301-2309. PubMed ID: 32757056 [TBL] [Abstract][Full Text] [Related]
19. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display. Koho T; Ihalainen TO; Stark M; Uusi-Kerttula H; Wieneke R; Rahikainen R; Blazevic V; Marjomäki V; Tampé R; Kulomaa MS; Hytönen VP Eur J Pharm Biopharm; 2015 Oct; 96():22-31. PubMed ID: 26170162 [TBL] [Abstract][Full Text] [Related]
20. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]